Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 88Neoplasm Metastasis 4HER2-positive Breast Cancer 4Stomach Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Thyroid Neoplasms 1Thrombocytosis 1Sarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Pathologic Complete Response 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Ado-Trastuzumab Emtansine × Breast × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04042051 2025-07-22

Panthera

Cancer Trials Ireland

Phase 1 Terminated
2 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Swiss Cancer Institute

Phase 2 Completed
208 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡